UPDATE: Piper Sandler Starts Aclaris Therapeutis (ACRS) at Overweight, $30 PT

June 15, 2021 6:21 AM EDT
Get Alerts ACRS Hot Sheet
Price: $15.34 +4.07%

Rating Summary:
    7 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 11 | New: 19
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - June 15, 2021 8:19 AM EDT)

Piper Sandler analyst Christopher Raymond initiates coverage on Aclaris Therapeutis (NASDAQ: ACRS) with an Overweight rating and a price target of $30.00.

The analyst commented, "Despite the stock’s ~176% YTD move, we believe the market continues to heavily discount the commercial potential of ACRS' two most advanced assets – ATI-450 an oral MK2 inhibitor with promising early data in RA and ATI-1777, an equally promising topical “soft” JAK1/3 inhibitor, for atopic dermatitis. While neither space is without competition, we think both compounds are each sufficiently differentiated so as to warrant blockbuster revenue potential. Importantly, both assets remain completely unencumbered. Combining this with the company’s proven internal discovery capabilities, we like the set up on this name and would be buyers into the $30/sh range."

For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.

Shares of Aclaris Therapeutis closed at $17.83 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage